OVDIEIBUCPNCT07269223
Oral Vitamin D3 Effect on Inflammatory Biomarkers in Ulcerative Colitis Patients
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Start date: Sep 2, 2025 to Dec 2, 2025 Show 7 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 13 words
- Trial completed
- Primary completion date changed from estimate of Dec 15, 2025 to Feb 15, 2026
- Study completion date changed from estimate of Dec 30, 2025 to Apr 30, 2026
- Secondary endpoints: 1 to 4
- Site details revised
- Notable Primary endpoints: 1 to 4
- Secondary endpoints expanded, about 12 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (4)
Arms and interventions
Intervention Type: Drug Intervention Name: Placebo Capsule Description: "An inactive oral placebo capsule that contains no Vitamin D3. It is matched in appearance and administration schedule to the active supplement and is used to maintain blinding."
Intervention Type: Drug Intervention Name: Vitamin D3 Description: "This intervention consists of oral Vitamin D3 (cholecalciferol) capsules administered every two weeks to improve vitamin D status. The dose is designed to raise serum 25(OH)D levels. Adherence will be monitored using supplement logs and follow-up visits."
Drugs: Vitamin D3
Sites
1 site in 1 country
- University of Veterinary & Animal Sciences, LahoreLahore, Punjab Province, Pakistan